Every hospital visit during lung cancer treatment can take hours. Travelling.
Waiting. Blood tests. Long infusion sessions. For many patients and families, treatment days become physically and mentally exhausting over time. A new immunotherapy injection launched in India may now reduce one part of that waiting time to around 7 minutes for some patients with Lung Cancer. In November 2025, Roche Pharma India introduced a subcutaneous injection version of Tecentriq in India. Unlike traditional IV infusions, this version is given under the skin instead of through a vein.
What is different about this version
Earlier, Tecentriq treatment was mainly given through intravenous (IV) infusion. Patients often had to sit for long treatment sessions during hospital visits. The newer version is given as an injection under the skin and takes around 7 minutes to administer.
For some patients, this may mean:
Less time spent in treatment chairs
Shorter hospital visits
Slightly easier treatment days
The medicine itself still contains atezolizumab, the same immunotherapy drug already used in cancer treatment.
Which cancers is it used for
Tecentriq is already part of treatment plans for several cancers, including:
Liver cancer
Certain breast cancers
Some advanced cancers
Doctors decide treatment based on:
Type of cancer
Stage of cancer
Previous treatments
Overall patient condition
Why shorter treatment time matters
Cancer treatment affects everyday life heavily. Many patients already feel exhausted from Repeated hospital visits, long waiting hours, Physical weakness, and travelling during treatment. So even reducing one part of the hospital process can feel meaningful for some families.
Not every patient will receive this injection
This treatment is not automatically suitable for everybody. Doctors still decide whether immunotherapy fits a patient’s condition. Scans, reports, previous treatments, and overall health all affect treatment decisions.
How immunotherapy works differently
Immunotherapy does not work exactly like chemotherapy. It helps the immune system recognize and attack cancer cells in certain patients. Some people respond well to it.
Others may respond differently. That is why treatment planning always depends on the individual patient and their cancer type.